U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07081984) titled 'Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors' on July 11.
Brief Summary: This is a phase I, open-label, dose escalation study evaluating the safety, tolerability, efficacy and immunogenicity of TI-0093 injection in patients with recurrent or metastatic HPV-16 positive solid tumors.
The primary objective of the study is to evaluate the safety and tolerability of TI-0093 injection in patients with recurrent or metastatic solid tumors, and to explore the maximal tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of TI-0093. The study schedule will include a 28-day screening, study treatme...